121 related articles for article (PubMed ID: 30318104)
1. Everolimus Rescue Treatment for Chronic Rejection After Pediatric Living Donor Liver Transplantation: 2 Case Reports.
Ueno T; Hiwatashi S; Saka R; Yamanaka H; Takama Y; Tazuke Y; Bessho K; Okuyama H
Transplant Proc; 2018 Nov; 50(9):2872-2876. PubMed ID: 30318104
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Everolimus Rescue Treatment After Pediatric Living Donor Liver Transplantation.
Ueno T; Kodama T; Noguchi Y; Deguchi K; Nomura M; Saka R; Watanabe M; Tazuke Y; Bessho K; Okuyama H
Transplant Proc; 2020; 52(6):1829-1832. PubMed ID: 32571711
[TBL] [Abstract][Full Text] [Related]
3. Revisiting chronic rejection following living donor liver transplantation in the tacrolimus era: A single center experience.
Choudhary NS; Saraf N; Saigal S; Gautam D; Rastogi A; Goja S; Bhangui P; Srinivasan T; Yadav SK; Soin A
Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29160909
[TBL] [Abstract][Full Text] [Related]
4. Antibody Drug Treatment for Steroid-Resistant Rejection After Pediatric Living Donor Liver Transplantation: A Single-Center Experience.
Hirata Y; Sanada Y; Urahashi T; Ihara Y; Yamada N; Okada N; Katano T; Otomo S; Ushijima K; Mizuta K
Transplant Proc; 2018; 50(1):60-65. PubMed ID: 29407332
[TBL] [Abstract][Full Text] [Related]
5. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation.
Takada Y; Kaido T; Asonuma K; Sakurai H; Kubo S; Kiuchi T; Inomata Y; Isaji S; Tsumura H; Teramukai S; Matsubara Y; Sakabayashi S; Uemoto S
Liver Transpl; 2013 Aug; 19(8):896-906. PubMed ID: 23696054
[TBL] [Abstract][Full Text] [Related]
6. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation.
Schuller S; Wiederkehr JC; Coelho-Lemos IM; Avilla SG; Schultz C
Transplant Proc; 2005 Mar; 37(2):1151-2. PubMed ID: 15848653
[TBL] [Abstract][Full Text] [Related]
7. [Case report of introducing MMF and steroids as an immunosuppressive therapy after living-donor liver transplantation for a patient with the diabetic nephropathy].
Kuramitsu S; Iguchi T; Ninomiya M; Yamashita Y; Harimoto N; Ikegami T; Uchiyama H; Yoshizumi T; Soejima Y; Shirabe K; Kawanaka H; Ikeda T; Furuta T; Tamada R; Maehara Y
Fukuoka Igaku Zasshi; 2014 Mar; 105(3):79-83. PubMed ID: 25000660
[TBL] [Abstract][Full Text] [Related]
8. Effect of everolimus rescue therapy for acute cellular rejection following pediatric living donor liver transplantation: Report of one case.
Hwang S; Namgoong JM; Oh SH; Kim KM; Ahn CS; Kwon H; Cho YJ; Kwon YJ
Ann Hepatobiliary Pancreat Surg; 2020 May; 24(2):216-220. PubMed ID: 32457270
[TBL] [Abstract][Full Text] [Related]
9. Serum Trough Concentration and Effects of Mycophenolate Mofetil Based on Pathologic Findings in Infants After Liver Transplantation.
Ueno T; Kodama T; Noguchi Y; Deguchi K; Nomura M; Saka R; Watanabe M; Tazuke Y; Bessho K; Okuyama H
Transplant Proc; 2020; 52(6):1855-1857. PubMed ID: 32571709
[TBL] [Abstract][Full Text] [Related]
10. Muromonab-CD3 for the successful treatment of early chronic rejection after pediatric liver transplantation: report of a case.
Hori T; Nguyen JH; Uemoto S
Surg Today; 2011 Apr; 41(4):585-90. PubMed ID: 21431500
[TBL] [Abstract][Full Text] [Related]
11. Chronic rejection associated with antiviral therapy for recurrent hepatitis C after living-donor liver transplantation.
Ueda Y; Kaido T; Ito T; Ogawa K; Yoshizawa A; Fujimoto Y; Mori A; Miyagawa-Hayashino A; Haga H; Marusawa H; Chiba T; Uemoto S
Transplantation; 2014 Feb; 97(3):344-50. PubMed ID: 24157473
[TBL] [Abstract][Full Text] [Related]
12. Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction.
Jain A; Sharma R; Ryan C; Tsoulfas G; Orloff M; Abt P; Kashyap R; Batzold P; Sauberman L; Safadjou S; Graham M; Bozorgzadeh A
Liver Transpl; 2008 Feb; 14(2):202-9. PubMed ID: 18236395
[TBL] [Abstract][Full Text] [Related]
13. Refractory Acute Antibody Mediated Rejection in Liver Transplant After Desensitization of Preformed Donor Specific Antibody-Validity of Bortezomib and Everolimus: A Case Report.
Komagome M; Maki A; Nagata R; Masuda W; Kogure R; Mitsui T; Ninomiya R; Akamatsu N; Hasegawa K; Beck Y
Transplant Proc; 2022; 54(1):147-152. PubMed ID: 34974892
[TBL] [Abstract][Full Text] [Related]
14. New strategy for ABO-incompatible living donor liver transplantation with anti-CD20 antibody (rituximab) and plasma exchange.
Kawagishi N; Satoh K; Enomoto Y; Akamatsu Y; Sekiguchi S; Fukumori T; Fujimori K; Satomi S
Transplant Proc; 2005 Mar; 37(2):1205-6. PubMed ID: 15848670
[TBL] [Abstract][Full Text] [Related]
15. Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: Results from a multicenter, prospective study.
Ganschow R; Ericzon BG; Dhawan A; Sharif K; Martzloff ED; Rauer B; Ng J; Lopez P
Pediatr Transplant; 2017 Nov; 21(7):. PubMed ID: 28714558
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of mycophenolate mofetil rescue therapy for resistant acute allograft rejection in pediatric liver transplant recipients.
Aw MM; Verma A; Rela M; Heaton N; Mieli-Vergani G; Dhawan A
Liver Transpl; 2008 Sep; 14(9):1303-8. PubMed ID: 18756458
[TBL] [Abstract][Full Text] [Related]
17. Intravenous mycophenolate mofetil with low-dose oral tacrolimus and steroid induction for live donor liver transplantation.
Jain A; Mohanka R; Orloff M; Abt P; Kashyap R; Kelley M; Burlee K; Bozorgzadeh A
Exp Clin Transplant; 2005 Dec; 3(2):361-5. PubMed ID: 16417444
[TBL] [Abstract][Full Text] [Related]
18. Two case reports of successful withdrawal of mycofenolate mofetil after living donor lobar lung transplantation.
Miyazaki T; Tagawa T; Yamasaki N; Tsuchiya T; Matsumoto K; Nagayasu T
Transplant Proc; 2013; 45(1):356-9. PubMed ID: 23375323
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppression based on everolimus in liver transplant recipients with severe early post-transplantation neurotoxicity.
Bilbao I; Dopazo C; Castells L; Lazaro J; Caralt M; Sapisochin G; Charco R
Transplant Proc; 2014 Nov; 46(9):3104-7. PubMed ID: 25420835
[TBL] [Abstract][Full Text] [Related]
20. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
